Result: Risk Minimisation Materials for medicines starting with the letter T

Tasmar

Meda Pharmaceuticals

Tasmar Patient Diary

To help you keep track of your appointments for liver function tests during the first year

Tecentriq

Roche Products Limited

Tecentriq (atezolizumab) Important Safety Information to Minimise the Risks of Immune-Related Adverse Reactions (for Healthcare Professionals)

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

For Healthcare Professionals

Tecentriq (atezolizumab) Patient Alert Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

Tenofovir

Generics UK T/A Mylan

Healthcare Professional Renal Management Ruler for patients taking Tenofovir Disoproxil for the Treatment of Hepatitis B

Renal Management and Dose Adjustment Advice for Healthcare Professionals with Adult Patients Receiving Tenofovir Disoproxil for the Treatment of Hepatitis B

For Healthcare Professionals

Healthcare Professional Renal Management Ruler for patients taking Tenofovir Disoproxil for the Treatment of HIV

Renal Management and Dose Adjustment Advice for Healthcare Professionals with Adult Patients Receiving Tenofovir Disoproxil for the Treatment of HIV

For Healthcare Professionals

Tenofovir HBV Paediactrics Brochure

Tenofovir HBV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Tenofovir HIV Paediactrics Brochure

Tenofovir HIV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Glenmark Pharmaceuticals Europe Ltd

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescent with HIV-1

HIV-1 Renal & bone effects education brochure - children and adolescent

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Chronic Hepatitis B education brochure – adolescent children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Chronic Hepatitis B education brochure – adults

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

HIV renal education brochure – adults

For Healthcare Professionals

Lupin Healthcare (UK) Ltd

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV1

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV1

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Accord Healthcare Limited

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1. If you require further information about Tenofovir and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B. If you require further information about Tenofovir and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B. If you require further information about Tenofovir and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV. If you require further information about Tenofovir and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Aurobindo Pharma - Milpharm Ltd.

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1

This brochure contains important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

This brochure provides important advice on the management of potential renal and bone effects of Tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

In adult patients with renal impairment, tenofovir disoproxil should only be used if the potential benefits of treatment outweigh the potential risks. A close monitoring of renal function is recommended.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

HIV-positive patients are at increased risk of renal impairment, requiring baseline and subsequent renal monitoring. For those adult patients on tenofovir disoproxil based regimens specific recommendations are detailed in the risk minimisation material

For Healthcare Professionals

Dr. Reddy's Laboratories (UK) Ltd

Renal and Bone Effects Risk Minimisation Material: Tenofovir Disoproxil for Children and Adolescents with HIV-1

HIV-1 Renal & bone effects education brochure - children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

HBV renal education brochure - children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

HBV renal education brochure – adults

For Healthcare Professionals

Renal Risk Minimisation Material: Tenofovir Disoproxil for Adults with HIV

HIV renal education brochure - adults

For Healthcare Professionals

Zentiva

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency – minimising the risks of renal and bone effects for children and adolescents with HIV

RENAL RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR ADULTS WITH HIV

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency - minimising the risks for Adults with HIV

Tenofovir disoproxil - Renal Risk Minimisation Adults with Chronic Hepatitis B

For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]

Tenofovir disoproxil - Renal Risk Minimisation for adolescent children

For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]

Cipla EU Ltd

RMM: TENOFOVIR DISOPROXIL FOR ADOLESCENT CHILDREN WITH CHRONIC HEPATITIS B

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADOLESCENT CHILDREN WITH CHRONIC HEPATITIS B

RMM: TENOFOVIR DISOPROXIL FOR ADULTS WITH CHRONIC HEPATITIS B

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADULTS WITH CHRONIC HEPATITIS B

RMM: TENOFOVIR DISOPROXIL FOR ADULTS WITH HIV

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADULTS WITH HIV

RMM: TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

Toctino

Stiefel

Toctino Patient Card

To be given by the dermatologist, specialist dermatology nurses, or prescribing GP to reinforce the key safety messages around risks.

Toctino Pharmacist Checklist

To be used as an aide memoire by pharmacists when dispensing oral retinoid medicines.

For Healthcare Professionals

Toctino Prescriber Checklist

To be used by the dermatologist, specialist dermatology nurse, or a prescribing GP with a special interest in dermatology to record the discussion of risks with the patient.

For Healthcare Professionals

Toujeo

SANOFI

Toujeo 300 units/ml, solution for injection in a pre-filled pen - Guide for Healthcare Professionals

This document is submitted as a guide to avoid medication errors and includes information which must be written on each prescription for Toujeo and key safety elements when switching from or to an insulin with a different strength. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

Toujeo 300 units/ml, solution for injection in a pre-filled pen - Guide for patients and/or carers

This document includes information such as what Toujeo is and how to use it. It is to be used as a guide alongside the full Instructions For Use leaflet which accompanies the pen. For hard copies please contact our medical information department at 01483 505515 or email [email protected]

Toujeo 300 units/ml, solution for injection in a pre-filled pen - Introduction letter

Important prescribing information for adults prescribed with Toujeo to avoid medication errors when switching to or from other Toujeo products. Please refer to the Patient Guide RMM and Instructions For Use leaflet which accompanies the pen. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

Tresiba

Novo Nordisk Limited

Tresiba® 100U and 200U FlexTouch® correct use of Tresiba® (insulin degludec)-to-minimise-medication-errors

Direct Healthcare Professional Communication for Tresiba® 100U and 200U FlexTouch® correct use of Tresiba® (insulin degludec) to minimise medication errors

For Healthcare Professionals

Triumeq

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Trizivir

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Trobalt

GlaxoSmithKline UK

Trobalt Physician's Guide

A guidance document for Healthcare Professionals prior to prescribing Trobalt to patients

For Healthcare Professionals

Truvada

Gilead Sciences Ltd

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Checklist For Prescribers

Checklist For Prescribers from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection

For Healthcare Professionals

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Patient Leaflet

Patient Leaflet from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection. It contains Important Information About Truvada® (emtricitabine/tenofovir disoproxil fumarate) to Reduce the Risk of Getting Human Immunodeficiency Virus (HIV) Infection for individuals who have been prescribed Truvada® for Pre-Exposure Prophylaxis (PrEP)

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Prescribers Leaflet

Important Safety Information for Prescribers About Truvada® (emtricitabine/tenofovir disoproxil fumarate) for a Pre-exposure Prophylaxis (PrEP) Indication

For Healthcare Professionals

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Reminder Card

Reminder Card for patients from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection.

Truxima

Napp Pharmaceuticals Limited

Truxima Administration Route

IV Infusion Only

For Healthcare Professionals

Truxima Patient Alert Card

Patient Alert Card

Truxima Patient Information

Information for Patients

Truxima Safety Sheet

Information for Healthcare Professionals

For Healthcare Professionals

Tysabri

Biogen Idec Ltd

Patient Alert Card

This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at [email protected] or by telephone on 0800 008 7401.

Physician Information and Management Guidelines for Multiple Sclerosis Patients on TYSABRI Therapy

This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.

For Healthcare Professionals

Treatment Continuation Form

This form should be read carefully before continuing TYSABRI treatment for more than 2 years.

Treatment Discontinuation Form

This form should be read carefully before discontinuing treatment with TYSABRI.

Treatment Initiation Form

This form should be read carefully before starting treatment with TYSABRI.